Cargando…

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Homet Moreno, B, Ribas, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453674/ https://www.ncbi.nlm.nih.gov/pubmed/25856776 http://dx.doi.org/10.1038/bjc.2015.124

Ejemplares similares

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
por: Lin, Emily M, et al.
Publicado: (2018)

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Tibaldi, Carmelo, et al.
Publicado: (2017)

Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
por: Hou, Yong-Zhe, et al.
Publicado: (2023)

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature
por: TSIOGKA, Aikaterini, et al.
Publicado: (2021)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Dynamic protein ligand interactions – insights from MS
por: Schmidt, Carla, et al.
Publicado: (2014)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Mechanisms of adverse effects of anti-VEGF therapy for cancer
por: Kamba, T, et al.
Publicado: (2007)

Targeting sphingosine-1-phosphate for cancer therapy
por: Sabbadini, R A
Publicado: (2006)

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy
por: Jo, Ukhyun, et al.
Publicado: (2015)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

Shattering the castle walls: Anti-stromal therapy for pancreatic cancer
por: Kanat, Ozkan, et al.
Publicado: (2018)

Emerging ethnic differences in lung cancer therapy
por: Sekine, I, et al.
Publicado: (2008)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Peroxiredoxins and the Regulation of Cell Death
por: Hampton, Mark B., et al.
Publicado: (2016)

Cell-Cell Signaling Proteobacterial LuxR Solos: a Treasure Trove of Subgroups Having Different Origins, Ligands, and Ecological Roles
por: Bez, Cristina, et al.
Publicado: (2023)

Targeting cell death signalling in cancer: minimising ‘Collateral damage'
por: Fox, Joanna L, et al.
Publicado: (2016)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Publicado: (2021)

Emerging Role of ZBP1 in Z-RNA Sensing, Influenza Virus-Induced Cell Death, and Pulmonary Inflammation
por: Basavaraju, Sharath, et al.
Publicado: (2022)

Anti-integrin therapy for inflammatory bowel disease
por: Park, Sung Chul, et al.
Publicado: (2018)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Actinide Organometallic Complexes with π‐Ligands
por: Walter, Olaf
Publicado: (2018)

Boron–Ligand Cooperation: The Concept and Applications
por: Hasenbeck, Max, et al.
Publicado: (2021)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Lipids and cell death in yeast
por: Eisenberg, Tobias, et al.
Publicado: (2014)

Endoscopic anti-reflux therapy for gastroesophageal reflux disease
por: Rodríguez de Santiago, Enrique, et al.
Publicado: (2021)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer
por: Safe, Stephen, et al.
Publicado: (2021)

Abracadabra, One Becomes Two: The Importance of Context in Viral −1 Programmed Ribosomal Frameshifting
por: Penn, Wesley D., et al.
Publicado: (2022)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2018)

Picornaviruses and Apoptosis: Subversion of Cell Death
por: Croft, Sarah N., et al.
Publicado: (2017)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

Functionalised N‐Heterocyclic Carbene Ligands in Bimetallic Architectures
por: Evans, Kieren J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lev0j7c1sfd3vjlm67pgre274h